← SynDRA
ATAMPARIB
SynDRA canonical compound SYN0040356 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | TIPARP |
|---|
| Mechanism of action | parp inhibitor |
|---|
| Indication | carcinoid tumors |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- PARP inhibitor
- TIPARP INHIBITOR
Cross-references
Synonyms
- RBN-2397
- ATAMPARIB (RBN-2397)
- RBN2397
- Atamparib [INN]
- UNII-B1MW2ME77A
- B1MW2ME77A
- SCHEMBL21521281
- BCP33764
- EX-A4038
- RBN2397;RBN 2397
- NSC825956
- s8993
- NSC-825956
- HY-136174
- CS-0120272
- 3(2H)-Pyridazinone, 5-(((1S)-1-methyl-2-(3-oxo-3-(4-(5-(trifluoromethyl)-2-pyrimidinyl)-1-piperazinyl)propoxy)ethyl)amino)-4-(trifluoromethyl)-
- 5-(((2S)-1-(3-Oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2- yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4- (trifluoromethyl)pyridazin-3(2H)-one
- Rbn 2397
- RefChem:115402
- PARP7 Inhibitor RBN-2397
- Atamparib [USAN]
- Atamparib [WHO-DD]
- Atamparib (USAN/INN)
- Atamparib [USAN:INN]
- orb1309170
- GTPL13118
- C20H23F6N7O3
- UQZCQKXJAXKZQH-LBPRGKRZSA-N
- BDBM431795
- GLXC-26409
- MFCD32701939
- WHO 11539
- AKOS040736567
- EBC-419041
- NCGC00842088-01
- AC-36483
- AS-76787
- DA-67127
- SY278680
Look up ATAMPARIB in the interactive SynDRA portal →